S1P receptor modulators
Immunology· 2 reviewed drugs· 5068 cited findings behind them
What the regulatory reviews cover
S1P receptor modulators reviewed in this library include Velsipity and Zeposia. Velsipity is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent. Zeposia is indicated for moderately to severely active ulcerative colitis (UC) in adults.
Regulatory reviews for these drugs report various efficacy outcomes. For Velsipity, the Mean difference from placebo in adapted MCS was -0.99. Zeposia demonstrated a Proportion of patients in clinical remission of 37 % compared to 19 % for placebo. It is important to note that different drugs were studied in different trials, and therefore, the reported figures are not head-to-head comparisons.
The drugs — one cited result each
| Velsipity Pfizer Inc. | Mean difference from placebo in adapted MCS: -0.99 Pfizer Inc. — Velsipity EMA EPAR public assessment report (E, p.91 |
| Zeposia Bristol-Myers Squibb Company | Proportion of patients in clinical remission: 37 % BRISTOL — Zeposia FDA Review (NDA/BLA 209899, 2023), p.57 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Immunology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.